Divis Lab Q3FY22 Preview: Revenue seen at Rs25,252 million, PAT at Rs7,388 million

3 Feb 2022 , 06:14 PM

Result date: 4th February, 2022

Recommendation: Add

Target price: Rs 4,320

(Source: IIFL Research)

Divis Lab is likely to post a good set of numbers in Q3 as revenue may increase by 48% YoY driven by QoQ increase in Molnupiravir revenue from ~USD35m to ~USD100m. Excluding Molnupiravir, the company’s base business revenue could grow only 5% YoY in Q3.

Company’s EBITDA could increase 52% as compared to the year ago quarter. PAT is likely to come higher by 57% YoY to Rs7,388 million.

Rs. Million	December 2021 estimates	YoY change	QoQ change
Revenue	25,252	48%	27%
EBITDA	10,479	52%	27%
PAT	7,388	57%	22%

Source: Company, IIFL Research